title: Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL.
authors.affiliation: Institute of Haematology and Medical Oncology L. e A. Seràgnoli, University of Bologna, Italy. simona.soverini@tin.it
authors.forename: Simona
authors.initials: S
authors.lastname: Soverini
authors.forename: Giovanni
authors.initials: G
authors.lastname: Martinelli
authors.forename: Sabrina
authors.initials: S
authors.lastname: Colarossi
authors.forename: Alessandra
authors.initials: A
authors.lastname: Gnani
authors.forename: Michela
authors.initials: M
authors.lastname: Rondoni
authors.forename: Fausto
authors.initials: F
authors.lastname: Castagnetti
authors.forename: Stefania
authors.initials: S
authors.lastname: Paolini
authors.forename: Gianantonio
authors.initials: G
authors.lastname: Rosti
authors.forename: Michele
authors.initials: M
authors.lastname: Baccarani
mesh_terms: D000293:Adolescent; D000368:Aged; D001549:Benzamides; D000069439:Dasatinib; D019008:Drug Resistance, Neoplasm; D016313:Genes, abl / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D010879:Piperazines / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D000069439:Dasatinib